-
Identification of specific PP2A complexes involved in human cell transformation Cancer Cell (IF 50.3) Pub Date : 2024-05-30 Wen Chen, Richard Possemato, K. Thirza Campbell, Courtney A. Plattner, David C. Pallas, William C. Hahn
No Abstract
-
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice Cancer Cell (IF 50.3) Pub Date : 2024-05-30 Jean-Philippe Gratton, Michelle I. Lin, Jun Yu, Erik D. Weiss, Zao Li Jiang, Todd A. Fairchild, Yasuko Iwakiri, Roberto Groszmann, Kevin P. Claffey, Yung-Chi Cheng, William C. Sessa
No Abstract
-
The temporal progression of lung immune remodeling during breast cancer metastasis Cancer Cell (IF 50.3) Pub Date : 2024-05-30 Christopher S. McGinnis, Zhuang Miao, Daphne Superville, Winnie Yao, Andrei Goga, Nathan E. Reticker-Flynn, Juliane Winkler, Ansuman T. Satpathy
-
Bispecific and multispecific antibodies in oncology: opportunities and challenges Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-05-31 Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf Bargou
-
A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy Mol. Cancer (IF 37.3) Pub Date : 2024-06-01 Na Li, Shinan Geng, Zhen-zhen Dong, Ying Jin, Hangjie Ying, Hung-Wing Li, Liyun Shi
Significant advancements have been made in the application of chimeric antigen receptor (CAR)-T treatment for blood cancers during the previous ten years. However, its effectiveness in treating solid tumors is still lacking, necessitating the exploration of alternative immunotherapies that can overcome the significant challenges faced by current CAR-T cells. CAR-based immunotherapy against solid tumors
-
N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2 Mol. Cancer (IF 37.3) Pub Date : 2024-05-31 Diguang Wen, Hang Xiao, Yueyi Gao, Hanqing Zeng, Jianchuan Deng
Elevated evidence suggests that the SENPs family plays an important role in tumor progression. However, the role of SENPs in AML remains unclear. We evaluated the expression pattern of SENP1 based on RNA sequencing data obtained from OHSU, TCGA, TARGET, and MILE datasets. Clinical samples were used to verify the expression of SENP1 in the AML cells. Lentiviral vectors shRNA and sgRNA were used to intervene
-
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype Specific Vulnerability in IDH2- and TET2-Mutant Cells Cancer Discov. (IF 28.2) Pub Date : 2024-05-31 Michael R. Waarts, Shoron Mowla, Meaghan Boileau, Anthony R. Martinez Benitez, Junya Sango, Maya Bagish, Ines Fernandez-Maestre, Yufan Shan, Shira E. Eisman, Young C. Park, Matthew Wereski, Isabelle Csete, Kavi O'Connor, Angelica C. Romero-Vega, Linde A. Miles, Wenbin Xiao, Xiaodi Wu, Richard P. Koche, Scott A. Armstrong, Alan H. Shih, Eirini P. Papapetrou, Jason M. Butler, Sheng F. Cai, Robert L.
Clonal hematopoiesis (CH) is a common premalignant state in the blood and confers an increased risk of blood cancers and all-cause mortality. Identification of therapeutic targets in CH has been hindered by the lack of an ex vivo platform amenable for studying primary hematopoietic stem and progenitor cells (HSPCs). Here, we utilize an ex vivo co-culture system of HSPCs with bone marrow endothelial
-
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models Clin. Cancer Res. (IF 11.5) Pub Date : 2024-05-31 Sheryl M. Gough, John J. Flanagan, Jessica Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John Corradi, Katherine Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang
Purpose: Estrogen Receptor (ER) alpha signaling is a known driver of ER-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Combining endocrine therapy (ET) such as fulvestrant with CDK4/6, mTOR or PI3K inhibitors is now a central strategy for the treatment of ER+ advanced breast cancer. However, suboptimal ER inhibition and resistance resulting from ESR1 mutation
-
Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort Clin. Cancer Res. (IF 11.5) Pub Date : 2024-05-31 Pauline Corbaux, Gilles Freyer, Olivier Glehen, Benoit You, Naoual Bakrin, Audrey Gelot, David Dayde, Christophe Sajous, Max Piffoux, Julien Peron, Gaelle Lescuyer, Léa Payen, Vahan Kepenekian
Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be synergistic with intraperitoneal (IP) immunotherapy by increasing tumor antigen expression and mutational load. We assessed the feasibility and safety of IP nivolumab following complete CRS and HIPEC in pretreated patients with recurrent ovarian cancer (ClinicalTrials.gov identifier: NCT03959761)
-
CHIPing away at proteomics to find correlations with myeloid neoplasms Clin. Cancer Res. (IF 11.5) Pub Date : 2024-05-31 Avni M. Bhalgat, Justin Taylor
Plasma proteomic profiling to identify associations with myeloid neoplasm (MN) risk, highlights the potential of integrating protein and genetic biomarkers for detection individuals at high-risk of developing MN. These proteins also offer valuable insights into biological pathways and inflammatory mechanisms involved in the progression of clonal hematopoiesis (CH) to MN.
-
Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity Cancer Res. (IF 11.2) Pub Date : 2024-05-31 Joash D. Joy, Beatrice Malacrida, Florian Laforets, Panoraia Kotantaki, Eleni Maniati, Ranjit Manchanda, Alessandro Annibaldi, Sarah Hopkins, Ianire Garrobo-Calleja, Julien Gautrot, Frances R. Balkwill
In vitro preclinical testing of chimeric antigen receptor (CAR) T cells is mostly carried out in monolayer cell cultures. However, alternative strategies are needed to take into account the complexity and the effects of the tumor microenvironment (TME). Here, we describe the modulation of CAR T cell activity by malignant cells and fibroblasts in human 3D in vitro cell models of increasing complexity
-
Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Kristiyana Kaneva, Christine Lo, Farahnaz Islam, Seung Won Hyun, Daniel Neems, Jason Yamada-Hanff, Terri Driessen, Hala Boulos, Chithra Sangli, Richard Blidner, Hideaki Bando, Robert Tell, Daisuke Kotani, Kate Sasser, Halla Nimeiri, Eiji Oki, Takayuki Yoshino
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3618-3618, June 2024.
-
Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Fathima Shehnaz Ayoobkhan, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola A. Abdallah, Weijing Sun, Faiz Anwer, Gary C. Doolittle, Joseph McGuirk, Raed Moh'd Taiseer Al-Rajabi, Joaquina Celebre Baranda, Nausheen Ahmed
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15080-e15080, June 2024.
-
Evaluation of concordance between blood-based and matched tissue molecular testing in a regional cancer center. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Carlos E Zuazo, Taylor Brodie, David R. Braxton, Burton Larry Eisenberg, Michael J. Demeure
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15062-e15062, June 2024.
-
Blood metabolites–based MCTarg for multi-cancer screening and clinical diagnosis. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Xinping Xu, Chunyan Zeng, Bei Qing, Li Liu, Guodong Song, Shuqi Yu, Tianqi Shao, Qingyan Wei, He Wen, Junyuan Hu, Wei Zhang, Youxiang Chen, Zhenkun Xia
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15028-e15028, June 2024.
-
Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Govind Panchamoorthy, Deepak Raina, Brian Lawney, Surender Kharbanda, Ravi Jasuja
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15025-e15025, June 2024.
-
Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Ganessan Kichenadasse, John J. Park, Sagun Parakh, Gary Edward Richardson, Mark Voskoboynik, John D. Powderly, Zhengbo Song, Shutong Liu, Yaling Huang, Shu-Hui Liu, Xun Meng
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e15010-e15010, June 2024.
-
Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Teodora Kuzmanovic, Maedeh Zokaei Nikoo, Lesil Brihn, Vicky Konig, Tejuana Watson, Teana Austin, Lauren Bokovitz, Tapas Ranjan Behera, Gabriel Savage, Megan Kilbane, Elizabeth M. Azzato, Zheng Jin Tu, Wen Wee Ma, Roberto Vargas, Jacob Miller, Emrullah Yilmaz, Ying Ni
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3159-3159, June 2024.
-
Total toxicity burden as a practical tool to quantify the overall severity of multiple adverse events in clinical trials. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Ruitao Lin, Pablo Alvarez-Ballesteros, Erick Campbell, Hung Le, Ecaterina Elena Dumbrava, Timothy A. Yap, David S. Hong, Funda Meric-Bernstam, Peter F. Thall, Jordi Rodon Ahnert, Berta Martin Cullell
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3156-3156, June 2024.
-
Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Siqing Fu, David S. Hong, Sarina A. Piha-Paul, Aung Naing, Jordi Rodon Ahnert, Timothy A. Yap, Daniel D. Karp, Ecaterina Elena Dumbrava, John Heymach, Jaffer A. Ajani, Carrie Cartwright, Jennifer Beck, Clark R. Andersen, Michael Kahle, David J. Vining, Jeffrey S. Ross, Calvin Y. Chao, Donald A. Berry, Funda Meric-Bernstam
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3153-3153, June 2024.
-
Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Elie G. Dib, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene Ahn, Ajjai Shivaram Alva, Navid Hafez, Evthokia Hobbs, Mehmet Akce, Deepti Behl, Carmen Julia Calfa, Timothy Lewis Cannon, Meredith McKean, Ramya Thota, Allison Paige Watson, Kathleen J Yost, Abby Gregory, Susan Halabi, Richard L. Schilsky
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3142-3142, June 2024.
-
Single cell characterization of persistent cells upon immunotherapy treatment in colorectal and endometrial tumors: The SERPENTINE trial. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Carmen García Durán, Paula Nieto, Juan Francisco Grau Béjar, Gerard Deuner, David García-Illescas, Ginevra Caratu, Lorena Fariñas-Madrid, Miren Berasategi, Marta Grzelak, Asaf Rotem, Juan Luis Melero, Patricia Casbas-Hernandez, Nick Borcherding, Juan Nieto, Alena Gros, Josep Tabernero, Ana Oaknin, Elena Elez, Holger Heyn
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3139-3139, June 2024.
-
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Do-Youn Oh, Elena Garralda, Maria Vieito, Julius Huang, Sarina A. Piha-Paul
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3125-3125, June 2024.
-
Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Hongyun Zhao, Jianhua Chen, Zhengbo Song, Yanqiu Zhao, Yubiao Guo, Gang Wu, Hua Yang, Xiaoqing Yu, Fangfang Gao, Ruiguang Zhang, Jian Fang, Xiaoyan Lin, GuangLin Liu, Chen Yang, Lichuang Men, Eric Liang, Dajun Yang, Li Zhang, Yifan Zhai
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3124-3124, June 2024.
-
Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Manish Sharma, Reinhard Dummer, Ilaria Colombo, Egle Ramelyte, Leigh Seamon, Drew W. Rasco, Victor Rodriguez Freixinos, Vito Dozio, Tri Tat, Noemie Luong, Aliaksandr Hurynovich, Mokhtar Omar, Sandrine Micallef, Anne Bellon, Esteban Rodrigo Imedio, Anastasios Stathis
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3120-3120, June 2024.
-
Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Toshinari Yamashita, Takanori Ishida, Kan Yonemori, Hiroji Iwata, Akihiko Shimomura, Kenjiro Aogi, Kenichi Inoue, Toru Mukohara, Takahiro Nakayama, Hitomi Sakai, Shigehisa Kitano, Shingo Kobayashi, Takuya Nakada, Ippei Suzuki, Yohei Otake, Junji Tsurutani
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3103-3103, June 2024.
-
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009). J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Anthony B. El-Khoueiry, Angela Tatiana Alistar, Hani M. Babiker, Devalingam Mahalingam, Minal A. Barve, Joohyuk Sohn, Mitesh J. Borad, Jae Cheol Lee, Jiye Ahn, Dayoung Lee, Jinho Choi, Jeongjun Kim, Dong-Hoon Yu, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Jaeseung Kim, Kiyean Nam
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3078-3078, June 2024.
-
A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Matteo Repetto, Justin Jee, Jason C. Chang, Pier Selenica, Andrea Gazzo, Allison L. Richards, Mark Donoghue, Carol Aghajanian, Jorge S. Reis-Filho, Britta Weigelt, Alexander E. Drilon, Robin Guo
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3073-3073, June 2024.
-
Utility of [18F]FDG PET/CT in predicting pathological complete response to neoadjuvant therapy in breast cancer: A prospective study. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Martina Sollini, Roberta Zanca, Paola Tiberio, Rita De Sanctis, Bethania Fernandes, Marcello Rodari, Arturo Chiti, Lidija Antunovic, Armando Santoro
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3070-3070, June 2024.
-
Therapeutic implications of phosphoproteomics in molecular cancer diagnostics. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Julia Woortman, Cecilia Bang Jensen, Amirhossein Sakhteman, Maria-Veronica Teleanu, Peter Horak, Simon Kreutzfeldt, Barbara Hutter, Jennifer Huellein, Moritz Resch, Christoph Stange, Chien-Yun Lee, Olaf Witt, David T.W. Jones, Daniel Hübschmann, Stefan M. Pfister, Wilko Weichert, Matthew The, Stefan Froehling, Bernhard Kuster
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3068-3068, June 2024.
-
Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Akash Mitra, John Guittar, Ryan D. Gentzler, Regina M. Schwind, Adam Joseph Dugan, Yan Liu, Seung Won Hyun, Michelle M. Stein, Kate Sasser, Rotem Ben-Shachar, Halla Nimeiri, Jyoti D. Patel, Aadel A Chaudhuri
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3046-3046, June 2024.
-
High-sensitive multi-cancers early detection for 8 cancer types by cell-free DNA targeted methylation sequencing: A retrospective cohort study. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Pansong Li, Wei Wei, Yong-Bin Lin, Hong Yang, Han Yang, Kong-Jia Luo, Xiaoman Hu, Haibo Qiu, Shu-Qiang Yuan, Yuan-fang Li, Xiao-Jun Lin, Bo-kang Cui, Li Xu, Rong-Xin Zhang, Wenhua Fan, Chunyan Lan, Ting Wan, Qi-hua Zhang, Rui-Hua Xu
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3043-3043, June 2024.
-
Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Sara M. Tolaney, Aditya Bardia, Javier Cortes, Frederik Marmé, Peter Schmid, Lisa A. Carey, Sibylle Loibl, Kevin Kalinsky, Joyce O'Shaughnessy, Sara A. Hurvitz, Theresa Valdez, Ya Meng, Wendy Verret, Scott T. Tagawa
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3029-3029, June 2024.
-
First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE). J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Sean Dulloo, Simon Lord, Fiona Thistlethwaite, Kevin G Blyth, Peter Wojciech Szlosarek, Nick Maskell, Sanjay Popat, Avinash Aujayeb, Burak Y Aktas, Sohail Rooman Javed, Julio Herrero Colomina, Brian Cunniff, Jarrett Duncan, Philippa Graham, Alice Susannah Bexon, George N Naumov, James F. Spicer
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3019-3019, June 2024.
-
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Jian Fang, Yan Yu, Qian Chu, Xiaoyan Li, Jiayan Chen, Zhe Liu, Li Zhang, Lin Wu, Wu Zhuang, XingYa Li, Yanqiu Zhao, Ligang Xing, Lian Liu, Chunmei Bai, Xiaorong Dong, Qibin Song, Pinghua Pan, Xuefeng Fang, Jie Wang
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3008-3008, June 2024.
-
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Nehal J. Lakhani, Amita Patnaik, Elizabeth Katherine Lee, Martin Gutierrez, Kathleen N. Moore, Benedito A. Carneiro, John L. Hays, Marilyn Huang, Patricia LoRusso, Andrew Wylie, Louise Cadzow, Matthew Goulet, Erica Tobin, Oliver Krieter, Daniela Schmid, Sophia M. Blake, Max Dieterich, Candice Jamois, Patricia M. Harris
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3005-3005, June 2024.
-
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Michael Bitzer, Christopher Hackenbruch, Jens Bauer, Yacine Maringer, Annika Nelde, Helmut R. Salih, Juliane S. Walz
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2702-TPS2702, June 2024.
-
EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Diane M. Simeone, Caleb Joshua Smith, Theodore H Welling, Kedar Kirtane, Patrick Grierson, Maria Pia Morelli, J. Randolph Hecht, Sandip Pravin Patel, Frederick L. Locke, Wen-Kai Weng, Marwan Fakih, Judy G. Vong, Kirstin B. Liechty, Eric Wai-Choi Ng, John Sutton Welch, Marcela Valderrama Maus, David G. Maloney, William Y. Go, Salman Rafi Punekar
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2698-TPS2698, June 2024.
-
DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Jonathan Robert Thompson, Amy Jensen-Smith, Ann Ranger, Ping Fan, Stanislav Katina, Pauline Duhard, Andrew Scott Paulson
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2681-TPS2681, June 2024.
-
A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Alla Keyzner, Hyung C. Suh, Uday R. Popat, Saar Gill, Yi-Bin Albert Chen, Melhem M. Solh, Lohith Gowda, Erica Buonomo, Yun Wang, Jim Murray, Gavin MacBeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2678-TPS2678, June 2024.
-
Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on potent anti-tumor activity via PD-1 checkpoint inhibition and conditional IL-2R agonism. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Zijuan Li, Feifei Zhang, Ze Zhang
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14697-e14697, June 2024.
-
Incidence of brain metastases within the VA Healthcare System. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Joseph Kamel Salama, Matthew J. Boyer
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14691-e14691, June 2024.
-
Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Anirban B. Ganguly, Jason Hafron, Jonathan Kaufman, Michael Chancellor
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14687-e14687, June 2024.
-
The evolving landscape of tissue-agnostic therapies in precision oncology CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-05-30 Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, Howard A. Burris, Razelle Kurzrock
Tumor-agnostic therapies represent a paradigm shift in oncology by altering the traditional means of characterizing tumors based on their origin or location. Instead, they zero in on specific genetic anomalies responsible for fueling malignant growth. The watershed moment for tumor-agnostic therapies arrived in 2017, with the US Food and Drug Administration's historic approval of pembrolizumab, an
-
Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial). J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Hitomi Sumiyoshi Okuma, Kenji Tsuchihashi, Ryunosuke Machida, Ryo Sadachi, Akihiro Hirakawa, Masahisa Kamikura, Kenta Anjo, Shigeki Sekine, Natsuko Tsuda Okita, Kenichi Nakamura, Kan Yonemori
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14603-e14603, June 2024.
-
First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Lihua Wu, Yong Li, Jinhua Wen, Junli Xue, Zhuoyi Wang, Pu Li, Wei Zhao, Jingfeng Liu, Xi Rao, Qun Li, Liqiong Xue, Xiaoxiao Ge, Fengjuan Lin, Wenbo Tang, Jiuli Zhou
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2662-2662, June 2024.
-
Exploring the diagnostic potential of cerebrospinal fluid (CSF) IL-10:IL-6 ratio in patients with primary central nervous system lymphoma (PCNSL). J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Aastha Takkar Kapila, Gaurav Prakash, Vivek Lal, Vishali Gupta, Ranjana Walker Minz, karthik Vinay Mahesh
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14041-e14041, June 2024.
-
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Anjie Zheng, Yuhong Xu, Xiaochen Zhang, Jinsong Wu
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e14030-e14030, June 2024.
-
Initial results from phase I trial of a novel oncolytic adenovirus Ad-TD-nsIL12 in recurrent glioblastoma connecting to ventricular system. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Weihai Ning, Yuduo Guo, Shenglun Li, Dixiang Song, Deshan Liu, Lixin Ma, Yujia Chen, Chao Zhao, Jiacheng Xu, Yanming Qu, Haoran Wang, Chunyu Gu, Mingshan Zhang, Yaohe Wang, Louisa Chard Dunmall, Shengdian Wang, Hongwei Zhang
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2057-2057, June 2024.
-
Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Colin Snyder, Zhihua Chen, Pawel Kalinski, Brian J. Czerniecki, Peter A. J. Forsyth
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2030-2030, June 2024.
-
Genomic biomarkers of CNS-specific outcomes in patients with breast cancer brain metastases. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Jordan Eichholz, Lillian A Boe, Anton Safonov, Deborah Ruth Smith, Emanuela Ferraro, Junchao Shen, Brandon S. Imber, Yao Yu, Yoshiya Yamada, Emily Miao, Nelson S. Moss, Jessica Wilcox, Henry S. Walch, Walid Khaled Chatila, Nikolaus Schultz, Pedram Razavi, Luke R. G. Pike
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2028-2028, June 2024.
-
Stereotactic radiosurgery in patients with small cell lung cancer and 1-10 brain metastases: A multi-institutional, phase II, prospective clinical trial. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Wenya Linda Bi, Paul J. Catalano, Fallon Chipidza, Daphne A. Haas-Kogan, Lauren Hertan, David E. Kozono, Monica Krishnan, Raymond H. Mak, Itai Pashtan, Luke Peng, Jack Qian, Rifaquat Rahman, Ivy Ricca, Jacob Sands, Ron Y. Shiloh, Kee-Young Shin, Shyam Kumar Tanguturi
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2020-2020, June 2024.
-
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Timothy Francis Cloughesy, Donald A. Berry, Meredith Becker Buxton, Howard Colman, Benjamin M. Ellingson, Gary B. Gordon, Andrew B. Lassman, Michael Lim, Ingo K. Mellinghoff, Erik P. Sulman, Michael Weller, Patrick Y. Wen, Emma Maria Viktoria Hyddmark, Tom Mikkelsen, Scott Peter Owen, Warren P. Mason, Jan Drappatz, Nicholas Alfred Blondin, James R. Perry
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 2005-2005, June 2024.
-
Genetic testing in cancer care: An assessment of current practice in Africa. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Katy Graef, Abba Aji Mallum, Aishat Oladipo, Fatoumata Ibrahim, Heng Li, Joerg Lehmann, Kavuma Awusi, Luca Incrocci, M. Saiful Huq, Marueen Bilinga Tendwa, Rohini Bhatia, Samuel Olaolu Adeneye, Solomon Kibudde, Stephen Avery, Thokozani Mkhize, Twalib Athumani Ngoma, Wil Ngwa, William Swanson, Adedayo Joseph
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13784-e13784, June 2024.
-
Incidence of mortality in vulnerable and non-vulnerable older patients with cancer. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 David Hernandez Barajas, Omar Alejandro Zayas Villanueva, Estefania Elizabeth Abundis Márquez, Elias Román Urdiales Hidalgo
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13775-e13775, June 2024.
-
Value of a multidisciplinary geriatric oncology committee on patient care in a community-based, academic cancer center. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Lena Morant, McKenzie Bedra, Jennifer Emel, Kelly Harris, Yudhishtra Markan, Christopher deBorja, Monica Tong, Patrice Downs, Cherif Boutros
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13771-e13771, June 2024.
-
Disparities in patients with HER2-positive breast cancer receiving optimal treatment: Analysis of the real-world ASCO CancerLinQ dataset. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Alyssa N Jones, Erica L. Mayer, Mariana Chavez-MacGregor, Tari A. King, Elizabeth A. Mittendorf
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13739-e13739, June 2024.
-
Mindfulness-based group medical visits: Strategies to improve equitable access and inclusion for diverse patients in cancer treatment. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Ivan C. Leung, Maria T. Chao, Ariana Thompson-Lastad, Christine Pollak, Anand Dhruva, Wendy Hartogensis, Michael Lister, Stephanie W. Cheng, Kavita K. Mishra
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13717-e13717, June 2024.
-
Racial/ethnic distribution of participants in NRG oncology clinical trials: 2014-2023. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Paul A Romitti, Sue S. Yom, Felix Y Feng, Jeffrey D. Bradley, Minesh P. Mehta, Deborah Watkins Bruner, Jennifer Wenzel, Eleftherios P. Mamounas, Thomas J. George, Theodore S. Hong, Carol Aghajanian, Maria Werner-Wasik, Alexandra Thomas
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13706-e13706, June 2024.
-
Black patient representation in anti-cancer drug development. J. Clin. Oncol. (IF 45.3) Pub Date : 2024-05-29 Rodrigo Paredes, Yu Fujiwara, Anna Argulian, Himanshu Joshi, Matt D. Galsky
Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page e13680-e13680, June 2024.